Search

everythinglearnresearchcommunity

for

Search:↓

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

The body's change of testosterone into DHT is not necessary for testosterone's muscle and sexual effects.

Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.

CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.

The methods accurately measured brain androgens, showing most 5α-androstane-3α,17β-diol comes from outside the brain, while androsterone is both transported and made in the brain.

Researchers created a new method to measure brain steroids, finding higher levels of certain steroids and changes due to a drug.

Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.

Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.

New steroids were patented as effective for treating acne, hair loss, and other conditions related to hormones.

A new method was developed to make finasteride for treating hair loss.

5α-reductases increase epitestosterone's effect on androgen receptors.

Natesto nasal gel improves erectile function and mood in men with low testosterone within 30 days.

Men with male-pattern baldness have higher levels of certain testosterone metabolites and may have more active androgen metabolism.

We need to learn more about 5α-reductases and neuroactive steroids to safely make drugs targeting these enzymes.

Researchers made two new compounds that could be used for medicine.

11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.

Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.

Testosterone affects androgen receptors and lipid storage in cells, while DHEA does not convert to testosterone or affect these receptors in the same way.

A new method was developed to make a compound used in finasteride and epristeride with a 69% yield.

A 17-year-old female with adrenogenital syndrome produces very high levels of androgens, which prevent complete feminization despite high estrogen doses.

New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.

The study found that urine metabolites M1b or M4 are the best indicators of ATD use in horses, with detection possible up to 77 hours in urine and 28 hours in blood.

New steroids were effective in blocking male hormone receptors in hamster prostates.

Platelet-rich plasma (PRP) shows promise in skin and hair treatments but results vary with preparation methods.

Martynia annua shows promise for future medical research due to its many medicinal properties.

Epitestosterone may counteract testosterone's effects and has roles in body processes like prostate growth and hair distribution.

PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

Hair loss can indicate underlying systemic diseases and addressing these can sometimes reverse the hair loss.